SCHEMBL4000183

SCHEMBL4000183

C=C(C(=O)OCC)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.48
▸ MAPT P10636 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CASP1 P29466 1/20 0.44
▸ HPGD P15428 2/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HDAC9 Q9UKV0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643972 0.83 TSHR (0.50) TSHRMAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL5059081 0.82 MAPT (0.55) TSHRMAPTALDH1A1SMN1; SMN2CASP1
SCHEMBL7079697 0.81 SMN1; SMN2 (0.53) TSHRMAPTALDH1A1SMN1; SMN2CASP1
SCHEMBL3256021 0.80 CA12 (0.61) TSHRALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL11270791 0.80 ALDH1A1 (0.57) TSHRMAPTALDH1A1SMN1; SMN2CASP1
SCHEMBL3903964 0.79 XPO1 (0.51) MAPTALDH1A1SMN1; SMN2CASP1HPGD
SCHEMBL11583511 0.79 ALDH1A1 (0.51) TSHRMAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL11580571 0.79 ALDH1A1 (0.51) TSHRMAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL5023402 0.79 ALDH1A1 (0.46) TSHRMAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL5023406 0.79 ALDH1A1 (0.46) TSHRMAPTALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470816-B2 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 — — US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 — — US disclosed
WO-2009072643-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT TSHR 396/4885MAPT 4420/4885ALDH1A1 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback